Titan Story

<div class='circular--portrait' style='background:#FF0000;color: #F8F8FF;font-size:4em;'>TP</div>
TTNP -- USA Stock  

USD 2.29  0.15  6.15%

Titan Pharma is scheduled to announce its earnings today. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to recap Titan Pharma under the recent economic conditions. We will analyze why Titan Pharma investors may still consider a stake in the business given the recent economic outlook.
Published over a week ago
View all stories for Titan Pharma | View All Stories
Our recent take on Titan (NASDAQ:TTNP) analyst consensus
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Titan Pharma has an asset utilization ratio of 36.43 percent. This suggests that the company is making $0.36 for each dollar of assets. An increasing asset utilization means that Titan Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Titan Pharma? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

How important is Titan Pharma's Liquidity

Titan Pharma financial leverage refers to using borrowed capital as a funding source to finance Titan Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Titan Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Titan Pharma's total debt and its cash.

How Titan utilizes its cash?

To perform a cash flow analysis of Titan Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Titan Pharma is receiving and how much cash it distributes out in a given period. The Titan Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Titan Pharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Titan Pharma reported last year Net Cash Flow from Operations of 5.66 Million

Is Titan a risky opportunity?

Let's check the volatility. Titan is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Titan (NASDAQ:TTNP) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. obtaining a share of a Titan Pharma stock makes you a part-owner of that company.

Will Titan insiders exit after the decline?

Recent Jensen Alpha is up to 0.04. Price may decline again. Titan Pharma exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Titan Pharma individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Titan Pharma future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Titan Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Titan Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Titan Pharma

Although some other companies in the biotechnology industry are either recovering or due for a correction, Titan may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Titan valuation and our trade advice on Titan Pharma is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Titan Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Titan Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com